PT-141 (bremelanotide, sold as Vyleesi) is an FDA-approved injectable peptide that works in the brain to increase sexual desire, approved for hypoactive sexual desire disorder in premenopausal women and studied off-label in men.
What it does
PT-141 is a melanocortin receptor agonist — meaning it binds to and activates a family of receptors in the brain called melanocortin receptors, particularly MC4R. When MC4R fires in the hypothalamic paraventricular nucleus (a region that coordinates hormonal and behavioral responses), it triggers dopaminergic signaling — the release of dopamine along the brain's reward and motivation pathways — which translates into increased sexual desire and arousal Andrew 2025 Donna 2025.
This central mechanism is what sets PT-141 apart from drugs like sildenafil (Viagra) or tadalafil (Cialis), which work peripherally by relaxing blood vessels in genital tissue. Because PT-141 acts upstream in the brain rather than on local vasculature, it may produce arousal in people who don't respond to PDE5 inhibitors Andrew 2025. It works through the same pathway in both men and women Donna 2025.
PT-141 was developed from Melanotan II (MT-2) research, after researchers noticed that MT-2 produced pronounced sexual side effects in subjects. PT-141 was engineered with better MC4R selectivity — it has less tanning effect and fewer off-target melanocortin side effects than MT-2, though some remain M 2025 Donna 2025.
What the evidence shows
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women Strong — two Phase 3 RCTs, FDA-approved
PT-141 is FDA-approved for HSDD in premenopausal women under the brand name Vyleesi. The pivotal trials — including a multicenter, randomized, double-blind, placebo-controlled study — showed statistically significant improvements in sexual desire scores and a reduction in distress related to low desire compared to placebo NCT01382719 NCT04943068. A systematic review and meta-analysis confirmed bremelanotide as an effective pharmacologic option for female sexual desire and arousal dysfunction Germano 2026. Multiple clinical pharmacology reviews have since incorporated it into treatment frameworks for HSDD Andrew 2025 Donna 2025.
Sexual dysfunction in cancer survivors Emerging — guideline mentions, limited trial data in this specific population
Several oncology survivorship guidelines and reviews now mention bremelanotide as a pharmacologic option for women experiencing sexual dysfunction after breast or gynecologic cancer treatment, particularly those on endocrine therapies where hormonal options are restricted Olivia 2025 Jessica 2025 K 2025. The evidence base here is largely extrapolated from the HSDD approval trials rather than cancer-specific RCTs, so this use is promising but not yet fully characterized in this population.
Male erectile dysfunction and anorgasmia Phase 2 human data for ED; single case report for anorgasmia
Phase 2 trial data exist for PT-141 in men with erectile dysfunction, including those who hadn't responded to PDE5 inhibitors, with results suggesting central arousal augmentation Andrew 2025 Donna 2025. No Phase 3 male ED trial has been completed, and PT-141 is not FDA-approved for men. A single case report noted first-time orgasm in a man with lifelong anorgasmia after treatment with flibanserin — another centrally acting agent — suggesting the pathway is relevant but the specific PT-141 evidence for this use remains anecdotal Gal 2023.
Sexual dysfunction related to PMDD and broader female sexual dysfunction Mechanistic rationale; limited clinical data specific to PMDD
There is a recognized clinical overlap between premenstrual dysphoric disorder (PMDD) and female sexual dysfunction, and bremelanotide's central mechanism has been discussed in this context Mahati 2024. Evidence specific to PMDD-associated sexual dysfunction is limited; the rationale rests on shared neurobiological pathways rather than dedicated trials.
Primary care management of sexual dysfunction Observational data on treatment gaps; no new efficacy trials
An observational study found a significant gap in how sexual dysfunction is managed between male and female patients in primary care settings, with female patients receiving fewer pharmacologic interventions E 2025. Bremelanotide is cited as an underutilized but approved option in this context — relevant for understanding the real-world uptake gap rather than adding new efficacy evidence.
How it's used
In studies and the FDA-approved label, the standard dose is 1.75 mg administered subcutaneously (injected under the skin, typically in the abdomen or thigh) approximately 45 minutes before anticipated sexual activity Donna 2025 NCT01382719. Some self-reported protocols start lower, at 0.75 mg, to assess tolerance before moving to the full dose. Doses above 2 mg are rarely used and not supported by trial data. The route in clinical trials is subcutaneous injection; an intranasal formulation was studied earlier but is not the current approved delivery method. Dosing is as-needed (PRN), not daily — the label caps use at one dose per 24 hours and approximately eight doses per month.
Side effects and safety
Nausea is the most commonly reported side effect — occurring in roughly 40% of subjects in pivotal trials — and is often the primary reason for discontinuation Donna 2025 NCT01382719. Flushing, headache, and injection-site reactions are also common. A transient increase in blood pressure typically peaking within 12 minutes and resolving within 12 hours has been documented; for this reason, PT-141 is contraindicated in people with uncontrolled hypertension or known cardiovascular disease Andrew 2025 Donna 2025. Skin hyperpigmentation (darkening) can occur with repeated use, a residual effect of its melanocortin activity M 2025. Vomiting occurs less frequently but is reported at meaningful rates. Severe cardiovascular events are theoretically possible in at-risk patients, which is why that population is excluded. Long-term safety data beyond the trial windows are limited — chronic use patterns, cumulative hyperpigmentation, and cardiovascular effects over years have not been well characterized. People with a history of migraines or hepatic/renal impairment should use caution.
Bottom line
PT-141 has genuine, FDA-backed evidence for HSDD in premenopausal women and a biologically coherent rationale for broader sexual dysfunction use in both sexes. The central mechanism makes it meaningfully different from PDE5 inhibitors, and Phase 2 male data are encouraging — but no approved male indication exists yet. Nausea and transient blood pressure elevation are real tolerability hurdles, and anyone with cardiovascular disease should avoid it entirely.